Health Catalyst (NASDAQ:HCAT) Given "Overweight" Rating at Piper Sandler

Health Catalyst (NASDAQ:HCAT - Get Free Report)'s stock had its "overweight" rating reaffirmed by research analysts at Piper Sandler in a research report issued on Tuesday,Benzinga reports. They currently have a $12.00 target price on the stock, up from their previous target price of $11.00. Piper Sandler's target price would indicate a potential upside of 39.86% from the stock's current price.

HCAT has been the subject of a number of other research reports. Stephens boosted their price objective on Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a research report on Thursday, November 14th. Royal Bank of Canada boosted their price objective on Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. Citigroup boosted their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Evercore ISI boosted their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. lifted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of "Moderate Buy" and an average target price of $11.79.

Health Catalyst Stock Performance

Shares of HCAT traded up $0.06 during mid-day trading on Tuesday, hitting $8.58. The stock had a trading volume of 212,692 shares, compared to its average volume of 559,778. The company has a market cap of $522.09 million, a PE ratio of -6.34 and a beta of 1.32. The company's fifty day simple moving average is $8.13 and its two-hundred day simple moving average is $7.28. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The company's revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities analysts expect that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the transaction, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. The trade was a 5.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,068 shares of company stock valued at $257,555 over the last three months. Company insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA grew its stake in Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company's stock valued at $15,205,000 after purchasing an additional 305,079 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Health Catalyst in the third quarter worth about $897,000. Essex Investment Management Co. LLC acquired a new stake in shares of Health Catalyst in the third quarter worth about $2,012,000. AQR Capital Management LLC acquired a new stake in shares of Health Catalyst in the second quarter worth about $564,000. Finally, Impax Asset Management Group plc lifted its position in shares of Health Catalyst by 16.4% in the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company's stock worth $20,793,000 after buying an additional 360,201 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.